Savoy Emily A, Olatunji Feyisola P, Mesbahi Nooshin, Ballard Ryanne K, Lovingier Christine L, Hendricksen Aaron T, Fulton Melody D, Berkman Clifford E
Washington State University, Department of Chemistry, Pullman, WA 99164-4630, United States.
Washington State University, Department of Chemistry, Pullman, WA 99164-4630, United States.
Bioorg Med Chem Lett. 2024 Mar 15;101:129657. doi: 10.1016/j.bmcl.2024.129657. Epub 2024 Feb 14.
Herein, we report the modular synthesis and evaluation of a prostate-specific membrane antigen (PSMA) targeted small molecule drug conjugate (SMDC) carrying the chemotherapeutic agent, SN38. Due to the fluorogenic properties of SN38, payload release kinetics from the platform was observed in buffers representing the pH conditions of systemic circulation and cellular internalization. It was found that this platform is stable with minimal payload release at physiological pH with most rapid payload release observed at pH values representing the endosome complex. We confirmed selective payload release and chemotherapeutic efficacy for PSMA(+) prostate cancer cells over PSMA(-) cells. These results demonstrate that chemotherapeutic agents with limited solubility can be conjugated to a water-soluble targeting and linker platform without attenuating efficacy.
在此,我们报告了一种携带化疗药物SN38的前列腺特异性膜抗原(PSMA)靶向小分子药物偶联物(SMDC)的模块化合成及评估。由于SN38的荧光特性,在代表体循环和细胞内化pH条件的缓冲液中观察到了药物从该平台的释放动力学。结果发现,该平台在生理pH下稳定,药物释放极少,而在代表内体复合物的pH值下观察到药物释放最快。我们证实了该药物对PSMA(+)前列腺癌细胞的选择性释放及化疗效果优于PSMA(-)细胞。这些结果表明,溶解度有限的化疗药物可与水溶性靶向和连接子平台偶联,而不会降低疗效。